Core Viewpoint - Lai Kai Pharmaceutical-B (2105.HK) has seen a significant stock price increase of over 7%, surpassing HKD 16, with a total market capitalization of HKD 7.1 billion, following a nearly 50% rise over the past eight trading days [1] Group 1: Company Developments - On November 12, Lai Kai Pharmaceutical granted rights for its breast cancer candidate drug LAE002 (afuresertib) to Qilu Pharmaceutical in China, with a total transaction amount of HKD 2.045 billion [1] - Lai Kai Pharmaceutical is entitled to receive a tiered sales commission ranging from 10% to over 20% from the sales of LAE002 [1] - LAE002 is one of the two AKT inhibitors in late-stage clinical development for breast and prostate cancer globally, ranking among the top two in progress and being the first domestically developed [1]
港股异动丨来凯医药续涨超7% 8日连涨超50% 乳腺癌明星靶点斩获20.45亿元BD大单